T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells. (Q40456521)

20 September 2017

title

T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells. (English)

1 reference

20 September 2017

author

Hans-Georg Kräusslich

6

object named as

Hans-Georg Kräusslich

1 reference

20 September 2017

Thomas Neumann

1

1 reference

20 September 2017

Isabel Hagmann

2

1 reference

20 September 2017

Sabine Lohrengel

3

1 reference

20 September 2017

Marintha L Heil

4

1 reference

20 September 2017

Cynthia A Derdeyn

5

1 reference

20 September 2017

Matthias T Dittmar

7

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

333

1 reference

20 September 2017

issue

2

1 reference

20 September 2017

page(s)

251-262

1 reference

Predicting the unpredictable: transmission of drug-resistant HIV.

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Nonrandom HIV-1 infection and double infection via direct and cell-mediated pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

A recombinant virus assay using full-length envelope sequences to detect changes in HIV-1 co-receptor usage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

A novel recombinant marker virus assay for comparing the relative fitness of hiv-1 reverse transcriptase variants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

The entry of entry inhibitors: a fusion of science and medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Implications of antiretroviral resistance on viral fitness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Loss of N-linked glycans in the V3-loop region of gp120 is correlated to an enhanced infectivity of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Role of the human immunodeficiency virus type 1 envelope gene in viral fitness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precur

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal: analysis of its role in enhancement of viral infectivity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

inferred from DOI database lookup

7 January 2021

based on heuristic

Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

inferred from DOI database lookup

7 January 2021

based on heuristic

Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.12.035

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2004.12.035

1 reference

20 September 2017

1 reference